Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

M Catarina Silva, Fleur M Ferguson, Quan Cai and 11 more

eLife · 2019 · CC BY

doi:10.7554/elife.45457

Abstract

Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. Positron emission tomography (PET) tracers that bind to pathological tau are used in diagnosis, but there are no current therapies to eliminate these tau species. We employed targeted protein degradation technology to convert a tau PET-probe into a functional degrader of pathogenic tau. The hetero-bifunctional molecule QC-01–175 was designed to engage both tau and Cereblon (CRBN), a substrate-receptor for the E3-ubiquitin ligase CRL4CRBN, to trigger tau ubiquitination and proteasomal degradation. QC-01–175 effected clearance of tau in frontotemporal dementia (FTD) patient-derived neuronal cell models, with minimal effect on tau from neurons of healthy controls, indicating specificity for disease-relevant forms. QC-01–175 also rescued stress vulnerability in FTD neurons, phenocopying CRISPR-mediated MAPT-knockout. This work demonstrates that aberrant tau in FTD patient-derived neurons is amenable to targeted degradation, representing an important advance for therapeutics.

References 97

  1. 1.

    Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, Geschwind MD, Tartaglia MC, Gao F, Gianni D, Sena-Esteves M, Geschwind DH, Miller BL, Farese RV, Gao FB. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Reports. 2012;2:789-798.

    Not in our library10.1016/j.celrep.2012.09.007

  2. 2.

    Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. Journal of Neuroscience. 2008;28:6926-6937.

    Not in our library10.1523/jneurosci.0800-08.2008

  3. 3.

    Brunden KR, Ballatore C, Crowe A, Smith AB, Lee VM, Trojanowski JQ. Tau-directed drug discovery for alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Experimental Neurology. 2010;223:304-310.

    Not in our library10.1016/j.expneurol.2009.08.031

  4. 4.

    Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E. Development of tau aggregation inhibitors for alzheimer's disease. Angewandte Chemie International Edition. 2009;48:1740-1752.

    Not in our library10.1002/anie.200802621

  5. 5.

    Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Structural & Molecular Biology. 2014;21:803-809.

    Not in our library10.1038/nsmb.2874

  6. 6.

    Cheng C, Fass DM, Folz-Donahue K, MacDonald ME, Haggarty SJ. Highly expandable human iPS Cell-Derived neural progenitor cells (NPC) and neurons for central nervous system disease modeling and High-Throughput screening. Current Protocols in Human Genetics. 2017;92:8-21.

    Not in our library10.1002/cphg.33

  7. 7.

    Chesselet MF, Carmichael ST. Animal models of neurological disorders. Neurotherapeutics. 2012;9:241-244.

    Not in our library10.1007/s13311-012-0118-9

  8. 8.

    Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer's Disease. 2013;34:457-468.

    Not in our library10.3233/jad-122059

  9. 9.

    Collins I, Wang H, Caldwell JJ, Chopra R. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. Biochemical Journal. 2017;474:1127-1147.

    Not in our library10.1042/bcj20160762

  10. 10.

    Congdon EE, Sigurdsson EM. Tau-targeting therapies for alzheimer disease. Nature Reviews Neurology. 2018;14:399-415.

    Not in our library10.1038/s41582-018-0013-z

  11. 11.

    Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH, Alzheimer's Disease Genetics Consortium. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics. 2012;21:3500-3512.

    Not in our library10.1093/hmg/dds161

  12. 12.
    Are Tau Aggregates Toxic or Protective in Tauopathies? · 2013
    No notice
  13. 13.

    Cromm PM, Samarasinghe KTG, Hines J, Crews CM. Addressing Kinase-Independent functions of fak via PROTAC-Mediated degradation. Journal of the American Chemical Society. 2018;140:17019-17026.

    Not in our library10.1021/jacs.8b08008

  14. 14.

    Cruts M, Van Broeckhoven C, Dickerson B. radfordC. Hodges' Frontotemporal Dementia. 2015.

    Not in our library

  15. 15.

    David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. Journal of Neurochemistry. 2002;83:176-185.

    Not in our library10.1046/j.1471-4159.2002.01137.x

  16. 16.

    de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201-1204.

    Not in our library10.1038/nature08890

  17. 17.

    Deger JM, Gerson JE, Kayed R. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. Aging Cell. 2015;14:715-724.

    Not in our library10.1111/acel.12359

  18. 18.

    Del Prete D, Rice RC, Rajadhyaksha AM, D'Adamio L. Amyloid precursor protein (APP) May act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration. Journal of Biological Chemistry. 2016;291:17209-17227.

    Not in our library10.1074/jbc.m116.733626

  19. 19.

    DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine. 2017;9:eaag0481.

    Not in our library10.1126/scitranslmed.aag0481

  20. 20.

    Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019;133:952-961.

    Not in our library10.1182/blood-2018-07-862953

  21. 21.

    Dolan PJ, Johnson GV. The role of tau kinases in Alzheimer's disease. Current Opinion in Drug Discovery & Development. 2010;13:595-603.

    Not in our library

  22. 22.

    Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSC-derived neurons. Cell. 2011;145:831-834.

    Not in our library10.1016/j.cell.2011.05.034

  23. 23.
    Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome · 2018
    No notice
  24. 24.

    Fischer ES, Böhm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM, Tichkule RB, Schebesta M, Forrester WC, Schirle M, Hassiepen U, Ottl J, Hild M, Beckwith RE, Harper JW, Jenkins JL, Thomä NH. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49-53.

    Not in our library10.1038/nature13527

  25. 25.

    Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, Kshirsagar MA, Boxer AL, Kosik KS, Miller BL, Huang Y. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports. 2013;1:226-234.

    Not in our library10.1016/j.stemcr.2013.08.001

  26. 26.

    Galvin JE, Howard DH, Denny SS, Dickinson S, Tatton N. The social and economic burden of frontotemporal degeneration. Neurology. 2017;89:2049-2056.

    Not in our library10.1212/wnl.0000000000004614

  27. 27.

    Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS, Bradner JE. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology. 2018;14:405-412.

    Not in our library10.1038/s41589-018-0010-y

  28. 28.
    Invited review: Frontotemporal dementia caused by microtubule‐associated protein tau gene ( MAPT ) mutations: a chameleon for neuropathology and neuroimaging · 2015
    No notice
  29. 29.

    Gobbi LC, Knust H, Körner M, Honer M, Czech C, Belli S, Muri D, Edelmann MR, Hartung T, Erbsmehl I, Grall-Ulsemer S, Koblet A, Rueher M, Steiner S, Ravert HT, Mathews WB, Holt DP, Kuwabara H, Valentine H, Dannals RF, Wong DF, Borroni E. Identification of three novel radiotracers for imaging aggregated tau in Alzheimer's disease with positron emission tomography. Journal of Medicinal Chemistry. 2017;60:7350-7370.

    Not in our library10.1021/acs.jmedchem.7b00632

  30. 30.

    Goedert M. Tau protein and neurodegeneration. Seminars in Cell & Developmental Biology. 2004;15:45-49.

    Not in our library10.1016/j.semcdb.2003.12.015

  31. 31.

    Götz J, Xia D, Leinenga G, Chew YL, Nicholas H. What renders TAU toxic. Frontiers in Neurology. 2013;4:72.

    Not in our library10.3389/fneur.2013.00072

  32. 32.

    Gu J, Congdon EE, Sigurdsson EM. Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. Journal of Biological Chemistry. 2013;288:33081-33095.

    Not in our library10.1074/jbc.m113.494922

  33. 33.

    Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: an emerging targeting technique for protein degradation in drug discovery. BioEssays. 2018;40:1700247.

    Not in our library10.1002/bies.201700247

  34. 34.

    Holt DP, Ravert HT, Dannals RF. Synthesis and quality control of [(18) F]T807 for tau PET imaging. Journal of Labelled Compounds & Radiopharmaceuticals. 2016;59:411-415.

    Not in our library10.1002/jlcr.3425

  35. 35.

    Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS. A chemoproteomic approach to query the degradable kinome using a Multi-kinase degrader. Cell Chemical Biology. 2018;25:88-99.

    Not in our library10.1016/j.chembiol.2017.10.005

  36. 36.

    Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Research. 2016;26:484-498.

    Not in our library10.1038/cr.2016.31

  37. 37.

    Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. The EMBO Journal. 2014;33:409-417.

    Not in our library10.1002/embj.201387098

  38. 38.

    Jiang B, Wang ES, Donovan KA, Liang Y, Fischer ES, Zhang T, Gray NS. Development of dual and selective degraders of Cyclin-Dependent kinases 4 and 6. Angewandte Chemie International Edition. 2019;13.

    Not in our library10.1002/anie.201901336

  39. 39.

    Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R. Tau positron emission tomographic imaging in aging and early alzheimer disease. Annals of Neurology. 2016;79:110-119.

    Not in our library10.1002/ana.24546

  40. 40.

    Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science. 2004;117:5721-5729.

    Not in our library10.1242/jcs.01558

All 97 references

Cited by papers we hold 11

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.